RHYTHM PHARMACEUTICALS, INC.: 10-Q filed 2024-08-06
What RHYTHM PHARMACEUTICALS, INC. reported in its quarterly report filed 2024-08-06 (fiscal Q2 2024): 43 published measures, 117 facts as tagged in accession 0001558370-24-011101.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2024-08-06
- Fiscal period
- fiscal Q2 2024
- Accession
- 0001558370-24-011101 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All RHYTHM PHARMACEUTICALS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 381,846,000 | USD | |
| At 2023-12-31 | 332,745,000 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 202,351,000 | USD | |
| At 2023-12-31 | 162,986,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 39,343,000 | USD | |
| At 2024-03-31 | 61,581,000 | USD | |
| At 2023-12-31 | 169,759,000 | USD | |
| At 2023-06-30 | 182,285,000 | USD | |
| At 2023-03-31 | 219,763,000 | USD | |
| At 2022-12-31 | 264,262,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 161,669,000 | USD | |
| At 2023-12-31 | 60,081,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | -32,261,000 | USD | 91 |
| 2024-01-01 to 2024-06-30 | -173,633,000 | USD | 182 |
| 2024-01-01 to 2024-03-31 | -141,372,000 | USD | 91 |
| 2023-04-01 to 2023-06-30 | -46,703,000 | USD | 91 |
| 2023-01-01 to 2023-06-30 | -98,882,000 | USD | 181 |
| 2023-01-01 to 2023-03-31 | -52,179,000 | USD | 90 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-06-30 | -69,819,000 | USD | 182 |
| 2023-01-01 to 2023-06-30 | -77,523,000 | USD | 181 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-06-30 | 47,000 | USD | 181 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-06-30 | 150,422,000 | USD | 182 |
| 2023-01-01 to 2023-06-30 | -1,098,000 | USD | 181 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-06-30 | 21,488,000 | USD | 182 |
| 2023-01-01 to 2023-06-30 | 66,655,000 | USD | 181 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | -1,068,369,000 | USD | |
| At 2023-12-31 | -894,736,000 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | 61,011,824 | shares | 91 |
| 2024-01-01 to 2024-06-30 | 60,577,691 | shares | 182 |
| 2023-04-01 to 2023-06-30 | 56,867,662 | shares | 91 |
| 2023-01-01 to 2023-06-30 | 56,788,757 | shares | 181 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | 61,011,824 | shares | 91 |
| 2024-01-01 to 2024-06-30 | 60,577,691 | shares | 182 |
| 2023-04-01 to 2023-06-30 | 56,867,662 | shares | 91 |
| 2023-01-01 to 2023-06-30 | 56,788,757 | shares | 181 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | -0.55 | USD/shares | 91 |
| 2024-01-01 to 2024-06-30 | -2.89 | USD/shares | 182 |
| 2023-04-01 to 2023-06-30 | -0.82 | USD/shares | 91 |
| 2023-01-01 to 2023-06-30 | -1.74 | USD/shares | 181 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | -0.55 | USD/shares | 91 |
| 2024-01-01 to 2024-06-30 | -2.89 | USD/shares | 182 |
| 2023-04-01 to 2023-06-30 | -0.82 | USD/shares | 91 |
| 2023-01-01 to 2023-06-30 | -1.74 | USD/shares | 181 |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | 479,000 | USD | 91 |
| 2024-01-01 to 2024-06-30 | 779,000 | USD | 182 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 973,000 | USD | |
| At 2023-12-31 | 1,341,000 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-06-30 | 18,125,000 | USD | 182 |
| 2023-01-01 to 2023-06-30 | 15,267,000 | USD | 181 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | -40,478,000 | USD | 91 |
| 2024-01-01 to 2024-06-30 | -180,363,000 | USD | 182 |
| 2023-04-01 to 2023-06-30 | -46,604,000 | USD | 91 |
| 2023-01-01 to 2023-06-30 | -99,127,000 | USD | 181 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 357,366,000 | USD | |
| At 2023-12-31 | 308,268,000 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 54,722,000 | USD | |
| At 2023-12-31 | 55,203,000 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 4,543,000 | USD | |
| At 2023-12-31 | 4,885,000 | USD |
Net finite-lived intangible assets
Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 6,601,000 | USD | |
| At 2023-12-31 | 7,028,000 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 17,598,000 | USD | |
| At 2023-12-31 | 14,867,000 | USD |
Net inventory
Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 11,994,000 | USD | |
| At 2023-12-31 | 8,624,000 | USD |
Selling, general and administrative expense
Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | 36,415,000 | USD | 91 |
| 2024-01-01 to 2024-06-30 | 70,797,000 | USD | 182 |
| 2023-04-01 to 2023-06-30 | 30,046,000 | USD | 91 |
| 2023-01-01 to 2023-06-30 | 54,674,000 | USD | 181 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | 30,194,000 | USD | 91 |
| 2024-01-01 to 2024-06-30 | 158,858,000 | USD | 182 |
| 2023-04-01 to 2023-06-30 | 33,543,000 | USD | 91 |
| 2023-01-01 to 2023-06-30 | 71,487,000 | USD | 181 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 61,095,949 | shares | |
| At 2023-12-31 | 59,426,559 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 1,108,269,000 | USD | |
| At 2023-12-31 | 1,064,302,000 | USD |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | -617,000 | USD | |
| At 2023-12-31 | 134,000 | USD |
Operating lease right-of-use asset
Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 3,696,000 | USD | |
| At 2023-12-31 | 781,000 | USD |
Operating lease liability
Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 4,117,000 | USD |
Other noncurrent liabilities
Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 35,596,000 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 48,077,000 | USD | |
| At 2023-12-31 | 48,262,000 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 8,644,000 | USD | |
| At 2023-12-31 | 8,931,000 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | -31,782,000 | USD | 91 |
| 2024-01-01 to 2024-06-30 | -172,854,000 | USD | 182 |
| 2023-04-01 to 2023-06-30 | -46,703,000 | USD | 91 |
| 2023-01-01 to 2023-06-30 | -98,882,000 | USD | 181 |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-06-30 | -173,633,000 | USD | 182 |
| 2023-01-01 to 2023-06-30 | -98,882,000 | USD | 181 |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | -33,999,000 | USD | 91 |
| 2024-01-01 to 2024-06-30 | -175,686,000 | USD | 182 |
| 2023-04-01 to 2023-06-30 | -46,711,000 | USD | 91 |
| 2023-01-01 to 2023-06-30 | -98,804,000 | USD | 181 |
Net income available to common stockholders
Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | -33,563,000 | USD | 91 |
| 2024-01-01 to 2024-06-30 | -174,935,000 | USD | 182 |
| 2023-04-01 to 2023-06-30 | -46,703,000 | USD | 91 |
| 2023-01-01 to 2023-06-30 | -98,882,000 | USD | 181 |
Nonoperating interest expense
Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | 4,603,000 | USD | 91 |
| 2024-01-01 to 2024-06-30 | 9,358,000 | USD | 182 |
| 2023-04-01 to 2023-06-30 | 3,303,000 | USD | 91 |
| 2023-01-01 to 2023-06-30 | 6,449,000 | USD | 181 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | 302,000 | USD | 91 |
| 2024-01-01 to 2024-06-30 | 824,000 | USD | 182 |
| 2023-04-01 to 2023-06-30 | -17,000 | USD | 91 |
| 2023-01-01 to 2023-06-30 | 34,000 | USD | 181 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | 8,696,000 | USD | 91 |
| 2024-01-01 to 2024-06-30 | 7,509,000 | USD | 182 |
| 2023-04-01 to 2023-06-30 | -99,000 | USD | 91 |
| 2023-01-01 to 2023-06-30 | 245,000 | USD | 181 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-06-30 | 2,731,000 | USD | 182 |
| 2023-01-01 to 2023-06-30 | 7,607,000 | USD | 181 |
Change in inventories
The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-06-30 | 3,370,000 | USD | 182 |
| 2023-01-01 to 2023-06-30 | 3,260,000 | USD | 181 |
Inspect the source
- Entity
- RHYTHM PHARMACEUTICALS, INC. / CIK 0001649904
- Captured
- 2026-09-21T17:23:23.073Z
- SEC response SHA-256
771747c78d141a669c089d047621c19af9216a296b9b4128ab8c04753f65f408
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001649904.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))